{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:58Z","timestamp":1786982758824,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40263-023-01040-5","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:01:56Z","timestamp":1697511716000},"page":"1009-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea"],"prefix":"10.1007","volume":"37","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"10357","key":"1040_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(22)01018-2","volume":"400","author":"L P\u00e9rez-Carbonell","year":"2022","unstructured":"P\u00e9rez-Carbonell L, Mignot E, Leschziner G, et al. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400(10357):1033\u201346.","journal-title":"Lancet"},{"issue":"5","key":"1040_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1513\/AnnalsATS.202006-696FR","volume":"18","author":"C Lal","year":"2021","unstructured":"Lal C, Weaver TE, Bae CJ, et al. Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. Ann Am Thorac Soc. 2021;18(5):757\u201368.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"1040_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jsmc.2022.06.012","volume":"17","author":"T Ono","year":"2022","unstructured":"Ono T, Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2022;17(3):485\u2013503.","journal-title":"Sleep Med Clin"},{"issue":"2","key":"1040_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.118.248120","volume":"366","author":"MG Baladi","year":"2018","unstructured":"Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367\u201376.","journal-title":"J Pharmacol Exp Ther"},{"key":"1040_CR5","unstructured":"TMC Pharma (EU) Ltd. Sunosi (solriamfetol) film-coated tablets: EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sunosi. Accessed 6 Sep 2023."},{"key":"1040_CR6","unstructured":"Axsome Therapeutics Inc. SUNOSI (solriamfetol) tablets, for oral use: US prescribing information. 2023. https:\/\/www.fda.gov\/. Accessed 6 Sep 2023."},{"issue":"7","key":"1040_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40265-019-01123-y","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Solriamfetol: first global approval. Drugs. 2019;79(7):785\u201390.","journal-title":"Drugs"},{"issue":"5","key":"1040_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40267-020-00720-2","volume":"36","author":"ED Deeks","year":"2020","unstructured":"Deeks ED, Heo YA. Solriamfetol in excessive daytime sleepiness: a profile of its use. Drugs Ther Perspect. 2020;36(5):173\u201380.","journal-title":"Drugs Ther Perspect."},{"issue":"4","key":"1040_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpdd.867","volume":"10","author":"K Zomorodi","year":"2021","unstructured":"Zomorodi K, Chen D, Lee L, et al. A randomized, double-blind, placebo- and positive-controlled, 4-period crossover study of the effects of solriamfetol on QTcF intervals in healthy participants. Clin Pharmacol Drug Dev. 2021;10(4):404\u201313.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"1040_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/0269881118796814","volume":"32","author":"LP Carter","year":"2018","unstructured":"Carter LP, Henningfield JE, Wang YG, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol. 2018;32(12):1351\u201361.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"1040_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/jcph.1402","volume":"59","author":"K Zomorodi","year":"2019","unstructured":"Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;59(8):1120\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1040_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","volume":"16","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102\u20138.","journal-title":"Sleep Med"},{"issue":"7","key":"1040_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.5665\/sleep.5968","volume":"39","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379\u201387.","journal-title":"Sleep"},{"issue":"2","key":"1040_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.chest.2018.11.005","volume":"155","author":"PJ Strollo Jr","year":"2019","unstructured":"Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364\u201374.","journal-title":"Chest"},{"issue":"3","key":"1040_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370.","journal-title":"Ann Neurol"},{"issue":"11","key":"1040_CR16","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","volume":"199","author":"PK Schweitzer","year":"2019","unstructured":"Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1040_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsz220","volume":"43","author":"A Malhotra","year":"2020","unstructured":"Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2020;43(2):1\u201311.","journal-title":"Sleep"},{"key":"1040_CR18","unstructured":"European Medicines Agency. Sunosi (international non-proprietary name solriamfetol): EU assessment report. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sunosi. Accessed 6 Sep 2023."},{"key":"1040_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpsychires.2022.08.018","volume":"155","author":"AD Krystal","year":"2022","unstructured":"Krystal AD, Benca RM, Rosenberg R, et al. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. J Psychiatr Res. 2022;155:202\u201310.","journal-title":"J Psychiatr Res"},{"issue":"7","key":"1040_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-020-00744-2","volume":"34","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Shapiro C, Mayer G, et al. Solriamfetol for the treatment of excessive daytime sleepiness in participants with narcolepsy with and without cataplexy: subgroup analysis of efficacy and safety data by cataplexy status in a randomized controlled trial. CNS Drugs. 2020;34(7):773\u201384.","journal-title":"CNS Drugs"},{"key":"1040_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.sleep.2019.11.1250","volume":"67","author":"HA Emsellem","year":"2020","unstructured":"Emsellem HA, Thorpy MJ, Lammers GJ, et al. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med. 2020;67:128\u201336.","journal-title":"Sleep Med"},{"issue":"1","key":"1040_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.chest.2021.02.033","volume":"160","author":"PK Schweitzer","year":"2021","unstructured":"Schweitzer PK, Mayer G, Rosenberg R, et al. Randomized controlled trial of solriamfetol for excessive daytime sleepiness in OSA: an analysis of subgroups adherent or nonadherent to OSA treatment. Chest. 2021;160(1):307\u201318.","journal-title":"Chest"},{"issue":"8","key":"1040_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1513\/AnnalsATS.202002-136OC","volume":"17","author":"TE Weaver","year":"2020","unstructured":"Weaver TE, Drake CL, Benes H, et al. Effects of solriamfetol on quality-of-life measures from a 12-week phase 3 randomized controlled trial. Ann Am Thorac Soc. 2020;17(8):998\u20131007.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"1040_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5664\/jcsm.8992","volume":"17","author":"PK Schweitzer","year":"2021","unstructured":"Schweitzer PK, Strohl KP, Mayer G, et al. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. J Clin Sleep Med. 2021;17(4):659\u201368.","journal-title":"J Clin Sleep Med"},{"issue":"10","key":"1040_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.5664\/jcsm.9384","volume":"17","author":"TE Weaver","year":"2021","unstructured":"Weaver TE, Pepin JL, Schwab R, et al. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021;17(10):1995\u20132007.","journal-title":"J Clin Sleep Med"},{"key":"1040_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.sleep.2023.01.022","volume":"103","author":"Y Winter","year":"2023","unstructured":"Winter Y, Mayer G, Kotterba S, et al. Solriamfetol real world experience study (SURWEY): initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany. Sleep Med. 2023;103:138\u201343.","journal-title":"Sleep Med"},{"key":"1040_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.sleep.2022.08.005","volume":"100","author":"A Malhotra","year":"2022","unstructured":"Malhotra A, Strollo PJ, Pepin J-L, et al. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Med. 2022;100:165\u201373.","journal-title":"Sleep Med"},{"issue":"9","key":"1040_CR28","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/ene.14888","volume":"28","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28(9):2815\u201330.","journal-title":"Eur J Neurol"},{"issue":"9","key":"1040_CR29","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393.","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"1040_CR30","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.mayocp.2020.08.033","volume":"96","author":"KD Gandhi","year":"2021","unstructured":"Gandhi KD, Mansukhani MP, Silber MH, et al. Excessive daytime sleepiness: a clinical review. Mayo Clin Proc. 2021;96(5):1288\u2013301.","journal-title":"Mayo Clin Proc"},{"key":"1040_CR31","unstructured":"Bioprojet Pharma. Wakix (pitolisant) film-coated tablets: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wakix. Accessed 6 Sep 2023."},{"key":"1040_CR32","unstructured":"UCB Pharma SA. Xyrem (sodium oxybate) 500 mg\/mL oral solution: EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xyrem. Accessed 6 Sep 2023."},{"key":"1040_CR33","unstructured":"European Medicines Agency. Modafinil-containing medicinal products: annex I, II, III, IV. 2011. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/modafinil. Accessed 6 Sep 2023."},{"key":"1040_CR34","unstructured":"Teva Pharmaceuticals USA Inc. PROVIGIL\u00ae (modafinil) tablets, for oral use, C-IV: US prescribing information. 2015. https:\/\/www.fda.gov\/. Accessed 6 Sep 2023."},{"key":"1040_CR35","unstructured":"Jazz Pharmaceuticals Inc. XYREM\u00ae (sodium oxybate) oral solution, CIII: US prescribing information. 2023. https:\/\/www.fda.gov\/. Accessed 6 Sep 2023."},{"key":"1040_CR36","unstructured":"Harmony Biosciences LLC. WAKIX\u00ae (pitolisant) tablets, for oral use: US prescribing information. 2022. https:\/\/www.fda.gov\/. Accessed 6 Sep 2023."},{"key":"1040_CR37","unstructured":"Teva Pharmaceuticals USA Inc. NUVIGIL\u00ae (armodafinil) tablets, for oral use, C-IV: US prescribing information. 2017. https:\/\/www.fda.gov\/. Accessed 6 Sep 2023."},{"issue":"7","key":"1040_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/00325481.2021.1948305","volume":"133","author":"R Rosenberg","year":"2021","unstructured":"Rosenberg R, Schweitzer PK, Steier J, et al. Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management. Postgrad Med. 2021;133(7):772\u201383.","journal-title":"Postgrad Med"},{"issue":"162","key":"1040_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0200-2021","volume":"30","author":"W Randerath","year":"2021","unstructured":"Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Respir Rev. 2021;30(162): 210200.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"1040_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5664\/jcsm.27497","volume":"5","author":"LJ Epstein","year":"2009","unstructured":"Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263\u201376.","journal-title":"J Clin Sleep Med"},{"key":"1040_CR41","unstructured":"Bioprojet Pharma. Ozawade (pitolisant) film-coated tablets: EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozawade. Accessed 6 Sep 2023."},{"issue":"5","key":"1040_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.7326\/M22-3473","volume":"176","author":"T Pitre","year":"2023","unstructured":"Pitre T, Mah J, Roberts S, et al. Comparative efficacy and safety of wakefulness-promoting agents for excessive daytime sleepiness in patients with obstructive sleep apnea: a systematic review and network meta-analysis. Ann Intern Med. 2023;176(5):676\u201384.","journal-title":"Ann Intern Med"},{"key":"1040_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/NSS.S404113","volume":"15","author":"S Zhan","year":"2023","unstructured":"Zhan S, Ye H, Li N, et al. Comparative efficacy and safety of multiple wake-promoting agents for the treatment of excessive daytime sleepiness in narcolepsy: a network meta-analysis. Nat Sci Sleep. 2023;15:217\u201330.","journal-title":"Nat Sci Sleep."},{"issue":"21","key":"1040_CR44","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.3390\/jcm11216302","volume":"11","author":"PY Chien","year":"2022","unstructured":"Chien PY, Kuo CY, Lin MH, et al. Pharmacological interventions for excessive daytime sleepiness in adults with narcolepsy: a systematic review and network meta analysis. J Clin Med. 2022;11(21):6302.","journal-title":"J Clin Med"},{"issue":"12","key":"1040_CR45","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.5664\/jcsm.9610","volume":"17","author":"S Ronnebaum","year":"2021","unstructured":"Ronnebaum S, Bron M, Patel D, et al. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. J Clin Sleep Med. 2021;17(12):2543\u201355.","journal-title":"J Clin Sleep Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01040-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01040-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T07:20:48Z","timestamp":1700724048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01040-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01040-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"17 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}